Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Daniel de Boer
|
| gptkbp:collaboratesWith |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:country |
gptkb:Netherlands
|
| gptkbp:focus |
rare genetic diseases
RNA therapies |
| gptkbp:founded |
2012
|
| gptkbp:founder |
Daniel de Boer
|
| gptkbp:headquarters_location |
gptkb:Leiden,_Netherlands
|
| https://www.w3.org/2000/01/rdf-schema#label |
ProQR Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ_Global_Market
|
| gptkbp:notable_clinical_trial |
Illuminate trial
Stellar trial |
| gptkbp:notableProduct |
QR-1123
QR-421a sepofarsen |
| gptkbp:numberOfEmployees |
100-200
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:researchInterest |
RNA editing
antisense oligonucleotides |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
PRQR
|
| gptkbp:therapeuticArea |
genetic disorders
inherited retinal diseases |
| gptkbp:website |
https://www.proqr.com/
|
| gptkbp:bfsParent |
gptkb:Henri_Termeer
|
| gptkbp:bfsLayer |
7
|